Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Hertz

Showing results (271-280 of 368) with videos related to

Pageof 37
Sort By:
Pharmacogenetics and Genomics|February 15, 2024
Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptomsYuqing Liang, Christina L Gersch, Jennifer Lehman, et al.
Neurology|April 13, 2000
Functional MR evaluation of temporal and frontal language dominance compared with the Wada testS Lehéricy, L Cohen, B Bazin, et al.
The Lancet. Diabetes & Endocrinology|June 14, 2019
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trialThomas R Pieber, Bruce Bode, Ann Mertens, et al.
Journal of Medical Internet Research|February 5, 2025
Remote Monitoring of Chemotherapy-Induced Peripheral Neuropathy by the NeuroDetect iOS App: Observational Cohort Study of Patients With CancerCiao-Sin Chen, Michael P Dorsch, Sarah Alsomairy, et al.
British Journal of Clinical Pharmacology|June 12, 2012
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposureDaniel L Hertz, Christine M Walko, Arlene S Bridges, et al.
BMJ Open Diabetes Research & Care|December 15, 2020
Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trialJohn B Buse, Bruce W Bode, Ann Mertens, et al.
Pharmacogenomics|January 7, 2021
Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapyFaisal Shakeel, Fang Fang, Jung Won Kwon, et al.
The Journal of Biological Chemistry|May 13, 2008
Blood pressure is regulated by an alpha1D-adrenergic receptor/dystrophin signalosomeJohn S Lyssand, Mia C DeFino, Xiao-bo Tang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2013
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxelD L Hertz, S Roy, A A Motsinger-Reif, et al.
Journal of Patient Safety|October 1, 2020
Improvement Initiative to Develop and Implement a Tool for Detecting Drug-Drug Interactions During Oncology Clinical Trial Enrollment Eligibility ScreeningLauren A Marcath, Taylor D Coe, Faisal Shakeel, et al.
Pageof 37

Showing results (271-280 of 368) with videos related to

Sort By:
Pageof 37
Pharmacogenetics and Genomics|February 15, 2024
Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptomsYuqing Liang, Christina L Gersch, Jennifer Lehman, et al.
Neurology|April 13, 2000
Functional MR evaluation of temporal and frontal language dominance compared with the Wada testS Lehéricy, L Cohen, B Bazin, et al.
The Lancet. Diabetes & Endocrinology|June 14, 2019
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trialThomas R Pieber, Bruce Bode, Ann Mertens, et al.
Journal of Medical Internet Research|February 5, 2025
Remote Monitoring of Chemotherapy-Induced Peripheral Neuropathy by the NeuroDetect iOS App: Observational Cohort Study of Patients With CancerCiao-Sin Chen, Michael P Dorsch, Sarah Alsomairy, et al.
British Journal of Clinical Pharmacology|June 12, 2012
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposureDaniel L Hertz, Christine M Walko, Arlene S Bridges, et al.
BMJ Open Diabetes Research & Care|December 15, 2020
Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trialJohn B Buse, Bruce W Bode, Ann Mertens, et al.
Pharmacogenomics|January 7, 2021
Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapyFaisal Shakeel, Fang Fang, Jung Won Kwon, et al.
The Journal of Biological Chemistry|May 13, 2008
Blood pressure is regulated by an alpha1D-adrenergic receptor/dystrophin signalosomeJohn S Lyssand, Mia C DeFino, Xiao-bo Tang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2013
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxelD L Hertz, S Roy, A A Motsinger-Reif, et al.
Journal of Patient Safety|October 1, 2020
Improvement Initiative to Develop and Implement a Tool for Detecting Drug-Drug Interactions During Oncology Clinical Trial Enrollment Eligibility ScreeningLauren A Marcath, Taylor D Coe, Faisal Shakeel, et al.
Pageof 37